Tags

Type your tag names separated by a space and hit enter

Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Front Immunol. 2021; 12:732135.FI

Abstract

Natural killer cells (NK cells) are the first line of the innate immune defense system, primarily located in peripheral circulation and lymphoid tissues. They kill virally infected and malignant cells through a balancing play of inhibitory and stimulatory receptors. In pre-clinical investigational studies, NK cells show promising anti-tumor effects and are used in adoptive transfer of activated and expanded cells, ex-vivo. NK cells express co-stimulatory molecules that are attractive targets for the immunotherapy of cancers. Recent clinical trials are investigating the use of CAR-NK for different cancers to determine the efficiency. Herein, we review NK cell therapy approaches (NK cell preparation from tissue sources, ways of expansion ex-vivo for "off-the-shelf" allogeneic cell-doses for therapies, and how different vector delivery systems are used to engineer NK cells with CARs) for cancer immunotherapy.

Links

Authors+Show Affiliations

Cell & Gene Therapy, Thermo Fisher Scientific, Frederick, MD, United States.

BioProduction, Thermo Fisher Scientific, Grand Island, NY, United States.

BioProduction, Thermo Fisher Scientific, Oslo, Norway.

Cell & Gene Therapy, Thermo Fisher Scientific, Frederick, MD, United States.

Cell & Gene Therapy, Thermo Fisher Scientific, Frederick, MD, United States.

Cell & Gene Therapy, Thermo Fisher Scientific, Frederick, MD, United States.

Cell & Gene Therapy, Thermo Fisher Scientific, Frederick, MD, United States.

MeSH

Allogeneic CellsCell EngineeringCell- and Tissue-Based TherapyFetal BloodHumansImmunotherapy, AdoptiveInduced Pluripotent Stem CellsKiller Cells, NaturalNeoplasmsReceptors, Chimeric AntigenTreatment Outcome

Pub Type(s)

Journal Article

Review

Language

eng

PubMed ID

34925314

Citation

Heipertz, Erica L., et al. "Current Perspectives On "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies." Frontiers in Immunology, vol. 12, 2021, p. 732135.

Heipertz EL, Zynda ER, Stav-Noraas TE, et al. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies. Front Immunol. 2021;12:732135.

Heipertz, E. L., Zynda, E. R., Stav-Noraas, T. E., Hungler, A. D., Boucher, S. E., Kaur, N., & Vemuri, M. C. (2021). Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies. Frontiers in Immunology, 12, 732135. https://doi.org/10.3389/fimmu.2021.732135

Heipertz EL, et al. Current Perspectives On "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies. Front Immunol. 2021;12:732135. PubMed PMID: 34925314.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies. AU - Heipertz,Erica L, AU - Zynda,Evan R, AU - Stav-Noraas,Tor Espen, AU - Hungler,Andrew D, AU - Boucher,Shayne E, AU - Kaur,Navjot, AU - Vemuri,Mohan C, Y1 - 2021/12/01/ PY - 2021/06/28/received PY - 2021/11/01/accepted PY - 2021/12/20/entrez PY - 2021/12/21/pubmed PY - 2022/2/11/medline KW - AAV delivery KW - CAR-NK cells KW - GMP manufacturing KW - NK cell expansion KW - immunotherapy KW - killer immune receptors KW - lentiviral delivery KW - natural killer cells SP - 732135 EP - 732135 JF - Frontiers in immunology JO - Front Immunol VL - 12 N2 - Natural killer cells (NK cells) are the first line of the innate immune defense system, primarily located in peripheral circulation and lymphoid tissues. They kill virally infected and malignant cells through a balancing play of inhibitory and stimulatory receptors. In pre-clinical investigational studies, NK cells show promising anti-tumor effects and are used in adoptive transfer of activated and expanded cells, ex-vivo. NK cells express co-stimulatory molecules that are attractive targets for the immunotherapy of cancers. Recent clinical trials are investigating the use of CAR-NK for different cancers to determine the efficiency. Herein, we review NK cell therapy approaches (NK cell preparation from tissue sources, ways of expansion ex-vivo for "off-the-shelf" allogeneic cell-doses for therapies, and how different vector delivery systems are used to engineer NK cells with CARs) for cancer immunotherapy. SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/34925314/Current_Perspectives_on_ DB - PRIME DP - Unbound Medicine ER -